Tempest Therapeutics Files 8-K on Definitive Agreement
Ticker: TPST · Form: 8-K · Filed: Dec 6, 2024 · CIK: 1544227
| Field | Detail |
|---|---|
| Company | Tempest Therapeutics, Inc. (TPST) |
| Form Type | 8-K |
| Filed Date | Dec 6, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: definitive-agreement, corporate-action, security-holders
TL;DR
Tempest Therapeutics filed an 8-K on Dec 3rd about a material agreement affecting security holders.
AI Summary
On December 3, 2024, Tempest Therapeutics, Inc. entered into a material definitive agreement related to its security holders. The company, formerly known as Millendo Therapeutics, Inc. and OvaScience, Inc., filed this 8-K report on December 6, 2024, detailing changes in its corporate structure and security holder rights.
Why It Matters
This filing indicates significant corporate actions and potential changes to the rights of Tempest Therapeutics' security holders, which could impact their investment.
Risk Assessment
Risk Level: medium — Material definitive agreements and modifications to security holder rights can introduce significant changes and potential risks for investors.
Key Players & Entities
- Tempest Therapeutics, Inc. (company) — Registrant
- Millendo Therapeutics, Inc. (company) — Former Company Name
- OvaScience, Inc. (company) — Former Company Name
- December 3, 2024 (date) — Date of earliest event reported
- December 6, 2024 (date) — Filing Date
FAQ
What is the nature of the material definitive agreement entered into by Tempest Therapeutics?
The filing indicates a "Material Definitive Agreement" was entered into on December 3, 2024, but the specific details of the agreement are not provided in this excerpt.
What are the key items reported in this 8-K filing?
The key items reported are Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, and Financial Statements and Exhibits.
When was Tempest Therapeutics, Inc. previously known by other names?
Tempest Therapeutics, Inc. was formerly known as Millendo Therapeutics, Inc. (name change date 20181207) and OvaScience, Inc. (name change date 20120308).
What is the state of incorporation for Tempest Therapeutics, Inc.?
Tempest Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Tempest Therapeutics, Inc.?
The business address is 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005.
Filing Stats: 750 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2024-12-06 16:15:32
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share TPST The Nasdaq Stock Mar
Filing Documents
- d899818d8k.htm (8-K) — 32KB
- d899818dex41.htm (EX-4.1) — 11KB
- 0001193125-24-272464.txt ( ) — 203KB
- tpst-20241203.xsd (EX-101.SCH) — 4KB
- tpst-20241203_def.xml (EX-101.DEF) — 13KB
- tpst-20241203_lab.xml (EX-101.LAB) — 22KB
- tpst-20241203_pre.xml (EX-101.PRE) — 14KB
- d899818d8k_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits Exhibit No. Exhibit Title or Description 4.1 Amendment No. 2, dated as of December 5, 2024, to Rights Agreement, dated as of October 10, 2023, as amended, by and between Tempest Therapeutics, Inc. and Computershare Trust Company, N.A., as rights agent. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Tempest Therapeutics, Inc. Date: December 6, 2024 By: /s/ Stephen Brady Stephen Brady President and Chief Executive Officer